Monday’s Market Insights: Seadrill Ltd (SDRL), SolarCity Corp (SCTY), Oracle Corporation (ORCL), Celator Pharmaceuticals Inc (CPXX)
Seadrill Ltd (NYSE:SDRL) fell 5.28% to $6.99 in pre-market trading due to falling oil prices. The commodity dipped this morning due to concerns surrounding China’s economic growth. China is the second largest global oil consumer and its production levels have slowed to six-year lows after the country came to the brink of an economic crisis. Furthermore, analysts are worried about Saudi Arabia’s growing glut of oil as a result of decreasing oil exports. Saudia Arabia is the global oil export leader and recent data shows that demand for oil exports is slowing as the country reported decelerating export figures for August. Separately, Seadrill released a statement this morning commenting on its implication in the investigation surrounding Petrobras and contracts awarded to Sevan Drilling between 2005 and 2008. Although Seadrill now has a 50% stake in Sevan, Seadrill did not have a stake in the company between 2005 and 2008. According to the 3 analysts polled by TipRanks in the last 3 months, 2 analysts are bearish on SeaDrill and 1 is staying on the sidelines. The average 12-month price target for the stock is $9, marking a nearly 22% potential upside from where the stock last closed.
SolarCity Corp (NASDAQ:SCTY) slipped 5.46% down to $41.75 after Gordon Johnson of Axiom initiated coverage on the company with a Sell rating and a $24 price target. The analyst issued the bearish rating noting that the company’s “adj-Cost of capital is above ROIC” and stated that the company is “engaging in Subprime lending practices, which have already spawned a number of class action lawsuits.” Furthermore, Johnson refers to risks surrounding the U.S. treasury department investigation of the company and gigafab risks that could lead to bankruptcy. Separately, the company’s UK subsidiary, Zep Solar, exited the UK market today due to the government subsidy cuts that supported solar power endeavors. According to the 10 analysts polled by TipRanks in the last 3 months, 8 are bullish on the company while 2 are staying on the sidelines. The average 12-month price target for the stock is $75.11, marking a 70% potential upside from current levels.
Click here to view Gordon Johnson’s past ratings and performance history.
Oracle Corporation (NYSE:ORCL) slipped more than 1.3% in pre-market trading down to $36.86 this morning due to a downgrade by Brendan Barnicle at Pacific Crest. The analyst downgraded the stock from Overweight to Sector Weight and removed its price target, noting that the company is in a transition phase as it moves to the cloud. Barnicle explained, “Oracle’s accelerated move to the cloud is likely to lower F2016 revenue… As other software vendors have transitioned to the cloud, they have typically had challenges guiding their business during the transition, especially if they only moved part of the business to the cloud. Oracle is likely to face these same challenges.” According to the 17 analysts polled by TipRanks in the last 3 months, 11 are bullish on Oracle, 1 is bearish, and 5 are staying on the sidelines. The average 12-month price target for the stock is $44.07, marking an 18% potential upside from current levels.
Click here to view Brendan Barnicle’s past ratings and performance history.
Celator Pharmaceuticals Inc (NASDAQ:CPXX) increased 4.52% in pre-market trading up to $1.85 after the company announced data from its Phase 3 study of CPX-351, now known as VYXEOS, a treatment for acute myeloid leukemia. The Data and Safety Monitoring Board completed the drug’s safety review of all patients and recommended that the study continue as planned. The study has 309 patients aging 60 to 75 with high-risk acute myeloid leukemia. According to the 2 analysts polled by TipRanks in the last 3 months, both are bullish on the company with an average 12-month price target of $12, marking an overwhelming 578% potential upside from current levels.